Literature DB >> 28939663

Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.

Jingying Zhou1, Man Liu1, Hanyong Sun2, Yu Feng1, Liangliang Xu1, Anthony W H Chan3, Joanna H Tong3, John Wong4, Charing Ching Ning Chong4, Paul B S Lai4, Hector Kwong-Sang Wang5, Shun-Wa Tsang5, Tyler Goodwin6, Rihe Liu6, Leaf Huang6, Zhiwei Chen7,8, Joseph Jy Sung2,9, King Lau Chow5, Ka Fai To3, Alfred Sze-Lok Cheng1,9.   

Abstract

OBJECTIVE: Myeloid-derived suppressor cells (MDSCs) contribute to tumour immunosuppressive microenvironment and immune-checkpoint blockade resistance. Emerging evidence highlights the pivotal functions of cyclin-dependent kinases (CDKs) in tumour immunity. Here we elucidated the role of tumour-intrinsic CDK20, or cell cycle-related kinase (CCRK) on immunosuppression in hepatocellular carcinoma (HCC).
DESIGN: Immunosuppression of MDSCs derived from patients with HCC and relationship with CCRK were determined by flow cytometry, expression analyses and co-culture systems. Mechanistic studies were also conducted in liver-specific CCRK-inducible transgenic (TG) mice and Hepa1-6 orthotopic HCC models using CRISPR/Cas9-mediated Ccrk depletion and liver-targeted nanoparticles for interleukin (IL) 6 trapping. Tumorigenicity and immunophenotype were assessed on single or combined antiprogrammed death-1-ligand 1 (PD-L1) therapy.
RESULTS: Tumour-infiltrating CD11b+CD33+HLA-DR- MDSCs from patients with HCC potently inhibited autologous CD8+T cell proliferation. Concordant overexpression of CCRK and MDSC markers (CD11b/CD33) positively correlated with poorer survival rates. Hepatocellular CCRK stimulated immunosuppressive CD11b+CD33+HLA-DR- MDSC expansion from human peripheral blood mononuclear cells through upregulating IL-6. Mechanistically, CCRK activated nuclear factor-κB (NF-κB) via enhancer of zeste homolog 2 (EZH2) and facilitated NF-κB-EZH2 co-binding to IL-6 promoter. Hepatic CCRK induction in TG mice activated the EZH2/NF-κB/IL-6 cascade, leading to accumulation of polymorphonuclear (PMN) MDSCs with potent T cell suppressive activity. In contrast, inhibiting tumorous Ccrk or hepatic IL-6 increased interferon γ+tumour necrosis factor-α+CD8+ T cell infiltration and impaired tumorigenicity, which was rescued by restoring PMN-MDSCs. Notably, tumorous Ccrk depletion upregulated PD-L1 expression and increased intratumorous CD8+ T cells, thus enhancing PD-L1 blockade efficacy to eradicate HCC.
CONCLUSION: Our results delineate an immunosuppressive mechanism of the hepatoma-intrinsic CCRK signalling and highlight an overexpressed kinase target whose inhibition might empower HCC immunotherapy. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Cellular Immunology; Hepatocellular Carcinoma; Immunotherapy

Mesh:

Substances:

Year:  2017        PMID: 28939663      PMCID: PMC5961939          DOI: 10.1136/gutjnl-2017-314032

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  48 in total

1.  Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling.

Authors:  Guobin He; Debanjan Dhar; Hayato Nakagawa; Joan Font-Burgada; Hisanobu Ogata; Yuhong Jiang; Shabnam Shalapour; Ekihiro Seki; Shawn E Yost; Kristen Jepsen; Kelly A Frazer; Olivier Harismendy; Maria Hatziapostolou; Dimitrios Iliopoulos; Atsushi Suetsugu; Robert M Hoffman; Ryosuke Tateishi; Kazuhiko Koike; Michael Karin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

2.  Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers.

Authors:  Shuet Theng Lee; Zhimei Li; Zhenlong Wu; Meiyee Aau; Peiyong Guan; R K Murthy Karuturi; Yih Cherng Liou; Qiang Yu
Journal:  Mol Cell       Date:  2011-09-02       Impact factor: 17.970

3.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

Review 4.  The history and future of targeting cyclin-dependent kinases in cancer therapy.

Authors:  Uzma Asghar; Agnieszka K Witkiewicz; Nicholas C Turner; Erik S Knudsen
Journal:  Nat Rev Drug Discov       Date:  2015-02       Impact factor: 84.694

5.  The driving circuit of HBx and androgen receptor in HBV-related hepatocarcinogenesis.

Authors:  Sheng-Han Wang; Shiou-Hwei Yeh; Pei-Jer Chen
Journal:  Gut       Date:  2014-03-05       Impact factor: 23.059

6.  A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients.

Authors:  Hai Feng; Zhuo Yu; Yuan Tian; Ying-Ying Lee; May S Li; Minnie Y Y Go; Yue-Sun Cheung; Paul B S Lai; Andrew M L Chan; Ka-Fai To; Henry L Y Chan; Joseph J Y Sung; Alfred S L Cheng
Journal:  J Hepatol       Date:  2014-12-09       Impact factor: 25.083

7.  Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.

Authors:  Suresh Kalathil; Amit A Lugade; Austin Miller; Renuka Iyer; Yasmin Thanavala
Journal:  Cancer Res       Date:  2013-02-19       Impact factor: 12.701

8.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

9.  Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.

Authors:  Kelly D Moynihan; Cary F Opel; Gregory L Szeto; Alice Tzeng; Eric F Zhu; Jesse M Engreitz; Robert T Williams; Kavya Rakhra; Michael H Zhang; Adrienne M Rothschilds; Sudha Kumari; Ryan L Kelly; Byron H Kwan; Wuhbet Abraham; Kevin Hu; Naveen K Mehta; Monique J Kauke; Heikyung Suh; Jennifer R Cochran; Douglas A Lauffenburger; K Dane Wittrup; Darrell J Irvine
Journal:  Nat Med       Date:  2016-10-24       Impact factor: 53.440

Review 10.  Cyclin-dependent kinases.

Authors:  Marcos Malumbres
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

View more
  48 in total

1.  Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression.

Authors:  Zhiwu Tan; Li Liu; Mei Sum Chiu; Ka-Wai Cheung; Chi Wing Yan; Zhe Yu; Boon Kiat Lee; Wan Liu; Kwan Man; Zhiwei Chen
Journal:  Oncoimmunology       Date:  2018-10-16       Impact factor: 8.110

Review 2.  Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.

Authors:  Zuyuan Lin; Di Lu; Xuyong Wei; Jianguo Wang; Xiao Xu
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

Review 3.  Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers.

Authors:  Manisit Das; Leaf Huang
Journal:  J Pharmacol Exp Ther       Date:  2018-12-12       Impact factor: 4.030

Review 4.  Neutrophils as potential therapeutic targets in hepatocellular carcinoma.

Authors:  Daniel Geh; Jack Leslie; Rob Rumney; Helen L Reeves; Thomas G Bird; Derek A Mann
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-01-12       Impact factor: 46.802

Review 5.  Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.

Authors:  Guoying Zhou; Patrick P C Boor; Marco J Bruno; Dave Sprengers; Jaap Kwekkeboom
Journal:  Br J Cancer       Date:  2021-08-16       Impact factor: 9.075

6.  AAV-Vectored Fms-Related Tyrosine Kinase 3 Ligand Inhibits CD34+ Progenitor Cell Engraftment in Humanized Mice.

Authors:  Lijun Ling; Xian Tang; Xiuyan Huang; Jingjing Li; Hui Wang; Zhiwei Chen
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-30       Impact factor: 4.147

7.  TRAF6 Regulates the Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Tumor-Bearing Host.

Authors:  Ge Song; Yue Zhang; Jie Tian; Jie Ma; Kai Yin; Huaxi Xu; Shengjun Wang
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 8.  Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.

Authors:  Kyoko Oura; Asahiro Morishita; Joji Tani; Tsutomu Masaki
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

Review 9.  Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives.

Authors:  Xuezhen Zeng; Simon E Ward; Jingying Zhou; Alfred S L Cheng
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

Review 10.  Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC.

Authors:  Yueqi Zhang; Hongbing Wang; Hua Xiao
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.